LLY

1,031.32

+2.27%↑

JNJ

247.77

+2.27%↑

ABBV

229.86

+2.64%↑

NVS

169.26

+2.47%↑

MRK

123.21

+3.1%↑

LLY

1,031.32

+2.27%↑

JNJ

247.77

+2.27%↑

ABBV

229.86

+2.64%↑

NVS

169.26

+2.47%↑

MRK

123.21

+3.1%↑

LLY

1,031.32

+2.27%↑

JNJ

247.77

+2.27%↑

ABBV

229.86

+2.64%↑

NVS

169.26

+2.47%↑

MRK

123.21

+3.1%↑

LLY

1,031.32

+2.27%↑

JNJ

247.77

+2.27%↑

ABBV

229.86

+2.64%↑

NVS

169.26

+2.47%↑

MRK

123.21

+3.1%↑

LLY

1,031.32

+2.27%↑

JNJ

247.77

+2.27%↑

ABBV

229.86

+2.64%↑

NVS

169.26

+2.47%↑

MRK

123.21

+3.1%↑

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Open

SectorHealthcare

1.47 -2

Buy Sell

Overview

Share price change

24h

Current

Min

1.46

Max

1.5899999999999999

Key metrics
By Trading Economics
Income	1.8M -32M
Sales	-166K 1.7M
Profit margin	-1,852.384
Employees	181
EBITDA	7.9M -29M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+220.95% upside

Dividends
By Dow Jones
Next Earnings	11 maj 2026

Market Stats
By TradingEconomics
Market Cap	48M 174M
Previous open	3.47
Previous close	1.47

News Sentiment

By Acuity

66%

34%

311 / 352 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

26 lut 2026, 22:04 UTC

Earnings

Coles 1st Half Net Profit Falls 11% on Worker Remediation Costs

26 lut 2026, 23:55 UTC

Market Talk

Gold Edges Higher as Traders Digest U.S.-Iran Talks -- Market Talk

26 lut 2026, 23:40 UTC

Acquisitions, Mergers, Takeovers

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- Update

26 lut 2026, 23:37 UTC

Market Talk

Japanese Stocks May Fall, Tracking Wall Street's Decline -- Market Talk

26 lut 2026, 23:32 UTC

Earnings

Why Nvidia's Huge Numbers Don't Settle the Latest AI Fears -- Heard on the Street -- WSJ

26 lut 2026, 23:19 UTC

Acquisitions, Mergers, Takeovers

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- WSJ

26 lut 2026, 23:18 UTC

Acquisitions, Mergers, Takeovers

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- WSJ

26 lut 2026, 23:12 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Global Equities Roundup: Market Talk

26 lut 2026, 23:12 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Netflix Gives Up in Bidding War Over Warner -- Market Talk

26 lut 2026, 23:01 UTC

Acquisitions, Mergers, Takeovers

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

26 lut 2026, 23:00 UTC

Acquisitions, Mergers, Takeovers

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

26 lut 2026, 23:00 UTC

Acquisitions, Mergers, Takeovers

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- Update

26 lut 2026, 22:55 UTC

Acquisitions, Mergers, Takeovers

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

26 lut 2026, 22:43 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

26 lut 2026, 22:43 UTC

Market Talk

RBA Hike In March Is Being Underpriced -- Market Talk

26 lut 2026, 22:33 UTC

Acquisitions, Mergers, Takeovers

Netflix Has 4 Days to Make a New Offer for Warner Bros. The Bidding War Continues. -- Barrons.com

26 lut 2026, 22:20 UTC

Acquisitions, Mergers, Takeovers

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- Update

26 lut 2026, 22:13 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Bidding War Over Warner Bros. Set to Continue -- Market Talk

26 lut 2026, 21:59 UTC

Earnings

D-Wave Quantum Stock Rises on Earnings. Why a Revenue Miss Doesn't Seem to Matter. -- Barrons.com

26 lut 2026, 21:58 UTC

Acquisitions, Mergers, Takeovers

Netflix Has 4 Days to Make a New Offer for Warner Bros. The Bidding War Continues. -- Barrons.com

26 lut 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

26 lut 2026, 21:49 UTC

Earnings

Coles 1H Net Profit Falls 11% on Worker Remediation Costs

26 lut 2026, 21:45 UTC

Earnings

Coles Expects One-Off Costs of Around A$7 Million in 1H to Complete Simplification Process

26 lut 2026, 21:44 UTC

Earnings

Coles Says Liquor Sales Fell 2.5% in First Seven Weeks of 3Q

26 lut 2026, 21:44 UTC

Earnings

Coles Expects Market to Remain Highly Competitive

26 lut 2026, 21:44 UTC

Earnings

Coles Says Supermarket Customers Remain Value Oriented

26 lut 2026, 21:43 UTC

Earnings

Coles Says Supermarket Sales Revenue Up 5.3% in First Seven Weeks of 3Q When Tobacco Excluded

26 lut 2026, 21:43 UTC

Earnings

Coles Says Supermarket Sales Revenue Up 3.7% in First Seven Weeks of 3Q

26 lut 2026, 21:42 UTC

Acquisitions, Mergers, Takeovers

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- WSJ

26 lut 2026, 21:41 UTC

Earnings

Acquisitions, Mergers, Takeovers

Warner Bros. Earnings Report Falls Short. What It Means for the Netflix Takeover Saga. -- Barrons.com

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

220.95% upside

12 Months Forecast

Average 4.75 USD 220.95%

High 7 USD

Low 2.5 USD

Based on 2 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Based on 2 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

311 / 352 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.